CloudBreak Discovery Corp. Closes Imperial X Transaction
CloudBreak or the
Company ) is pleased to announce that its transaction with Imperial X Plc (
Imperial X ) (see the Company s press releases dated September 2, 2020, January 8, 2021, and February 17, 2021) has now closed. Under the transaction, CloudBreak amalgamated with Howson Ventures Inc. (
Howson ), Cabox Gold Corp. (
Numberco Sub ) to form 1308402 B.C. Ltd. (
Amalco ), which is a subsidiary of Imperial X (the
Amalgamation ). In conjunction with closing, Imperial X also acquired certain assets in Anglo African Minerals Plc (
AAM ) and changed its name to Cloudbreak Discovery Plc .
As consideration under the proposed transaction, Imperial X issued an aggregate of approximately 149,568,471 Imperial X shares pro rata to the CloudBreak shareholders. Accordingly, each CloudBreak shareholder received approximately 4.6365 Imperial X shares in exchange for each CloudBreak share held. Following closing, as well
Small Cap Wrap - CyanConnode, Crossword Cybersecurity, Cohort and more.
The independent technology Group, today announced an unaudited trading update for its financial year ended 30 April 2021 and outlook for the current financial year. Trading performance for the year ended 30 April 2021 is in line with expectations. Net funds stronger than expected at c.£2m (30 April 2020: net debt of £4.7m; 31 October 2020: net debt of £6.1m).
26 May 2021
Dish of the day
Pharma C Investments (AQSE:PCIL) has listed as a SPAC on the Access Segment of the AQSE Growth Market. It is specifically seeking to take advantage of the dynamic regulatory environment surrounding legal Medicinal Cannabis. Successful £1m fundraising at 0.7p per share.
What’s cooking in the IPO kitchen?
UK SPAC (formerly Mountfield Group and now an AIM Rule 15 Shell) has applied for admission to the AQSE Growth Market. The Company recently raised £3.1m in a placing, giving the Company flexibility in pursuing a reverse take-over transaction. The Directors of the Company are currently in the process of identifying and assessing reverse takeover opportunities with a particular focus on the European medicinal cannabis sector. The Directors are working closely with specialists in this industry in order to evaluate opportunities. Due 3 June
TECC Capital plc is a SPAC applying to be listed on the Access Segment of the AQSE Growth Market with the intention to identify and acquire a suitable business opportunity or opportunities and undertake an acquisition or merger or a series of acquisitions or mergers. The focus will be investing in businesses which are developing and/or supporting the application of technology in innovative sectors such a
Small Cap Wrap - Alba Mineral Resources, Arkle Resources, Comptoir Group and more.
The owner and/or operator of Lebanese and Eastern Mediterranean restaurants, today announces that, following the lifting of the lockdown restrictions on Monday 17th May, all 21 company owned and 3 franchise managed sites have now reopened to trade. All appropriate measures are in place to ensure government guidelines concerning social distancing and customer safety are fully adhered to.
21 May 2021
Dish of the day
Oxford Cannabinoid Technologies Holdings PLC (LON:OCTP) has joined the Main Market (Standard). A pre-revenue pharmaceutical company with an objective to develop cannabinoid-based prescription medicines approved by regulatory agencies including the US Food and Drug Administration, the European Medicines Agency, and the Medicines and Products Healthcare Regulatory Authority. Their drug development strategy includes the development of proprietary cannabinoid derivatives, natural phyt
Small Cap Wrap - Thor Explorations, Imperial X, ADM Energy and more.
The natural resources investing company, has completed the sale of 188,778 shares in Superdielectrics Ltd for a total consideration of £849,501, a profit of £656,003.55 on ADM s original investment leaving ADM with a holding of 6,222 shares following the sale. ADM has received the proceeds from the sale of the investment.
20 May 2021
What’s cooking in the IPO kitchen?
Oxford Cannabinoid Technologies Holdings PLC to IPO onto the Standard List. They are a pre-revenue pharmaceutical company with an objective to develop cannabinoid-based prescription medicines approved by regulatory agencies including the US Food and Drug Administration, the European Medicines Agency, and the Medicines and Products Healthcare Regulatory Authority. Their drug development strategy includes the development of proprietary cannabinoid derivatives, natural phytocannabinoids and other drug compounds that interplay with the endo